At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ODD ODDITY Tech Ltd.
Not Yet Opened 09-08 16:00:00 EDT
13.03
-0.72
-5.27%
盘后13.00
-0.03-0.19%
19:58 EDT
High13.75Low12.99Vol1.10M
Open13.53D1 Closing13.75Amplitude5.50%
Mkt Cap600.77MTradable Cap372.33MTotal Shares46.12M
T/O14.55MT/O Rate3.83%Tradable Shares28.59M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Top News Today/Canada: Carney Vows to Backstop Economy Amid U.S. Trade Row
Dow Jones  ·  04:31
Top News Today/Canada: Carney Vows to Backstop Economy Amid U.S. Trade Row
Oddity Maintained at Hold as Marketing Efficiency Shows Early Improvement but Near-Term Acquisition Headwinds Persist
TIPRANKS  ·  09-08 19:15
Oddity Maintained at Hold as Marketing Efficiency Shows Early Improvement but Near-Term Acquisition Headwinds Persist
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  09-08 18:00
Calendar of U.S. Earnings Expected in the Week Ahead
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  09-04
Calendar of U.S. Earnings Expected in the Week Ahead
Oddity Tech CFO Lindsay Drucker Mann Disposes of USD 128,081.54 in Common Shares
Reuters  ·  09-04
Oddity Tech CFO Lindsay Drucker Mann Disposes of USD 128,081.54 in Common Shares
SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company
GlobeNewswire  ·  09-03
SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company
Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire  ·  09-01
Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Oddity Tech CFO Lindsay Drucker Mann Disposes of 39,360 Common Shares Worth $587,688.94
Reuters  ·  09-01
Oddity Tech CFO Lindsay Drucker Mann Disposes of 39,360 Common Shares Worth $587,688.94
Oddity Tech Files Initial Beneficial Ownership Statement for Director Dave Scott Cohen
Reuters  ·  08-29
Oddity Tech Files Initial Beneficial Ownership Statement for Director Dave Scott Cohen
Oddity Tech CFO Lindsay Drucker Mann Disposes of 3,493 Shares for $52,423.93
Reuters  ·  08-28
Oddity Tech CFO Lindsay Drucker Mann Disposes of 3,493 Shares for $52,423.93
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
GlobeNewswire  ·  08-25
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage
GlobeNewswire  ·  08-25
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage
Oddity Tech Names Ex-Morgan Stanley IM Executive David S. Cohen Independent Director, Audit Committee Member
Reuters  ·  08-21
Oddity Tech Names Ex-Morgan Stanley IM Executive David S. Cohen Independent Director, Audit Committee Member
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement
GlobeNewswire  ·  08-20
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement
Press Release: Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
Dow Jones  ·  08-06
Press Release: Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals
GlobeNewswire  ·  08-06
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire  ·  08-04
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise
GlobeNewswire  ·  08-03
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise
Press Release: Radiopharm Theranostics Reports Business Update
Dow Jones  ·  07-31
Press Release: Radiopharm Theranostics Reports Business Update
ODDITY Tech Shareholders Approve All Proposals at 2026 Annual Meeting
TIPRANKS  ·  07-31
ODDITY Tech Shareholders Approve All Proposals at 2026 Annual Meeting

Introduction

Company Name.
ODDITY Tech Ltd.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Oddity Tech Ltd. operates as a consumer tech company that builds and scales digital-first brands to disrupt beauty and wellness industries. The company serves consumers worldwide through its AI-driven online platform, deploying data science to identify consumer needs, and developing solutions in the form of beauty and wellness products. It owns IL MAKIAGE and SpoiledChild brands. The company was incorporated in 2013 and is headquartered in Tel Aviv, Israel with additional office in New York, New York.
Issue price:
--